/

Empresas

De

No verificado

Delve Bio, Inc.

Sobre qué escribimos

BiotecnologíaEventosIndustriaSaludVIH, SIDA y enfermedades autoinmunes

8 Comunicados de prensa

Ver todos los comunicados de prensa

14/11/2025

Eventos

Biotecnología

VIH, SIDA y enfermedades autoinmunes

Salud

Ciencia

Presentations at Association for Molecular Pathology 2025 Annual Meeting Spotlight Clinical Impact of Delve Bio’s Metagenomic Sequencing Test for Improving CNS Diagnosis

Fuente

Delve Bio, Inc.

Editor

1.00

0

20/10/2025

Ciencia

VIH, SIDA y enfermedades autoinmunes

Biotecnología

Medicina - Varios

Salud

Farmacéutica

Eventos

Ferias y Congresos

Industria

New Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/Encephalitis

Fuente

Delve Bio, Inc.

Editor

1.00

0

22/06/2025

Salud

VIH, SIDA y enfermedades autoinmunes

Biotecnología

Medicina - Varios

Farmacéutica

Eventos

Industria

New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing

Fuente

Delve Bio, Inc.

Editor

1.00

0

07/05/2025

Eventos

Industria

VIH, SIDA y enfermedades autoinmunes

Salud

Biotecnología

New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test

Fuente

Delve Bio, Inc.

Editor

1.00

0

07/04/2025

Eventos

Industria

Salud

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

Ciencia

Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting

Fuente

Delve Bio, Inc.

Editor

1.00

0

04/12/2024

Industria

Material médico sanitario

Salud

VIH, SIDA y enfermedades autoinmunes

Ciencia

Biotecnología

Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect

Fuente

Delve Bio, Inc.

Editor

1.00

0

21/11/2024

VIH, SIDA y enfermedades autoinmunes

Salud

Medicina - Varios

Industria

Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections

Fuente

Delve Bio, Inc.

Editor

1.00

0

12/11/2024

Industria

Biotecnología

VIH, SIDA y enfermedades autoinmunes

Salud

Ciencia

Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections

Fuente

Delve Bio, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0